Phase 3 data show lebrikizumab improves skin clearance and itch in children with moderate to severe atopic dermatitis, ...

Shastry is an assistant professor of dermatology at Northwestern Feinberg School of Medicine in Chicago. The information here represents her knowledge and experience as a medical professional. She was ...

The human monoclonal antibody known as tralokinumab-ldrm was tested and approved as a safe, effective treatment for pediatric patients with atopic dermatitis aged 12 to 17 years old. Originally ...

Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced positive, top-line results from the pivotal Phase 3 ADorable-1 trial evaluating efficacy and ...

Eli Lilly’s phase 3 ADorable-1 trial of Ebglyss in paediatric patients with moderate-to-severe atopic dermatitis meets primary and key secondary endpoints: Indianapolis Tuesday, ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch relief and clear skin for many patients in a clinical trial, without the ...

"These three-year data show that raising the bar in atopic dermatitis treatment to long-term total skin clearance was an achievable treatment goal for at least half of EBGLYSS Week 16 responders, ...

How do dermatologists diagnose atopic dermatitis? To diagnose atopic dermatitis, also called eczema, a board-certified dermatologist carefully examines your (or your child's) skin and asks questions. ...

Please provide your email address to receive an email when new articles are posted on . Combination lebrikizumab and topical corticosteroids outperformed topical corticosteroids alone in the treatment ...

(RTTNews) - Eli Lilly and Co. (LLY) announced that its Ebglyss monotherapy monthly injection demonstrated sustained and deep responses in patients with moderate-to-severe atopic dermatitis over three ...

Mild-to-moderate Atopic Dermatitis (AD) may be adequately treated with a combination of trigger avoidance, moisturizers, topical corticosteroids, calcineurin inhibitors and/or crisaborole. However, ...

MedPage Today brought together three expert leaders for a virtual roundtable discussion on atopic dermatitis: Moderator Peter Lio, MD, of Northwestern University Feinberg School of Medicine in Chicago ...